IO Biotech
IO Biotech is a pioneering biopharmaceutical company focused on developing off-the-shelf therapeutic cancer vaccines. Their mission is to improve outcomes for people with cancer by utilizing their innovative T-win® technology, which modulates the tumor microenvironment to enhance anti-tumor activity. The company is committed to establishing their vaccines as a backbone of combination therapy for cancer treatment, aiming to reshape the tumor microenvironment and stimulate immune responses against tumor cells.
Industries
Nr. of Employees
medium (51-250)
IO Biotech
Products
Clinical‑stage combination peptide vaccine program targeting immunoregulatory antigens
A clinical‑stage off‑the‑shelf peptide vaccine combination designed to activate T cells specific for immunoregulatory antigens and intended for use alone or in combination with immune checkpoint inhibitors in multiple solid tumor indications; supported by Phase 1/2 proof‑of‑concept data and ongoing pivotal and basket trials.
Preclinical peptide vaccine candidate targeting immunosuppressive enzymes
A preclinical peptide vaccine candidate designed to activate T cells specific for an immunosuppressive enzyme expressed in tumors to target tumor and immune‑suppressive cells and support IND‑enabling activities.
Peptide vaccine technology platform for tumor microenvironment modulation
A platform approach for designing peptide vaccines that deliver epitopes from immunoregulatory antigens to enable direct targeting of antigen‑expressing tumor and immunosuppressive cells and reprogram the tumor microenvironment toward a pro‑inflammatory state.
Clinical‑stage combination peptide vaccine program targeting immunoregulatory antigens
A clinical‑stage off‑the‑shelf peptide vaccine combination designed to activate T cells specific for immunoregulatory antigens and intended for use alone or in combination with immune checkpoint inhibitors in multiple solid tumor indications; supported by Phase 1/2 proof‑of‑concept data and ongoing pivotal and basket trials.
Preclinical peptide vaccine candidate targeting immunosuppressive enzymes
A preclinical peptide vaccine candidate designed to activate T cells specific for an immunosuppressive enzyme expressed in tumors to target tumor and immune‑suppressive cells and support IND‑enabling activities.
Peptide vaccine technology platform for tumor microenvironment modulation
A platform approach for designing peptide vaccines that deliver epitopes from immunoregulatory antigens to enable direct targeting of antigen‑expressing tumor and immunosuppressive cells and reprogram the tumor microenvironment toward a pro‑inflammatory state.
Services
Management and execution of clinical programs from early‑phase proof‑of‑concept studies through pivotal Phase 3 trials, including combination regimens with immune checkpoint inhibitors and multi‑cohort basket trials.
Preclinical and clinical translational studies including immune‑response assessments, biomarker analyses and standardized immunomonitoring assays to inform mechanism‑of‑action and clinical strategy.
Consultative and programmatic support for CMC planning, external manufacturing management and regulatory documentation to enable clinical supply and scale‑up for peptide‑based and combination products, and support for other biologic modalities.
Policy formulation and operational evaluation for expanded access programs, including criteria‑based assessment before initiation and re‑evaluation aligned to pivotal trial data.
Advisory and strategic support from experienced executives and board members in clinical development strategy, regulatory affairs, CMC and corporate transactions.
Management and execution of clinical programs from early‑phase proof‑of‑concept studies through pivotal Phase 3 trials, including combination regimens with immune checkpoint inhibitors and multi‑cohort basket trials.
Preclinical and clinical translational studies including immune‑response assessments, biomarker analyses and standardized immunomonitoring assays to inform mechanism‑of‑action and clinical strategy.
Consultative and programmatic support for CMC planning, external manufacturing management and regulatory documentation to enable clinical supply and scale‑up for peptide‑based and combination products, and support for other biologic modalities.
Policy formulation and operational evaluation for expanded access programs, including criteria‑based assessment before initiation and re‑evaluation aligned to pivotal trial data.
Advisory and strategic support from experienced executives and board members in clinical development strategy, regulatory affairs, CMC and corporate transactions.
Expertise Areas
- Peptide vaccine platform development for oncology
- Tumor microenvironment modulation targeting regulatory T cells and tumor‑associated macrophages
- Translational biomarker development and standardized immunomonitoring
- Preclinical in vivo immuno‑oncology models and mechanism‑of‑action studies
Key Technologies
- Peptide epitope delivery platforms
- Immunomonitoring assays (T‑cell activation, T‑cell receptor diversity)
- Preclinical tumor models for immuno‑oncology
- Translational biomarker panels and assay development